← brief for 2026-11-15 · Slowing decline
Finerenone in Patients with Focal Segmental Glomerulosclerosis.
Key takeaways
This large trial tested a drug called finerenone in 1,584 people with a specific type of kidney scarring. The drug slowed the decline of kidney function over 32 months. This is a strong result from a big, well-run study. It suggests this drug can help protect kidneys in this group.
Who did this work
Heerspink HJL · Neuen BL · Agarwal R · Cherney DZI · Lam CSP · Tuttle KR · Wanner C · Sarafidis P · Chertow GM · Friede T · Barratt J · Floege J
Source
Article · PubMed, the drug frontier · 2026 Nov 15
https://pubmed.ncbi.nlm.nih.gov/43034991/